Seroreactivity to Helicobacter pylori Antigens as a Risk Indicator of Gastric Cancer

  • Karami, Najmeh (HPGC Group, Medical Biotechnology Department, Biotechnology Research Center) ;
  • Talebkhan, Yeganeh (HPGC Group, Medical Biotechnology Department, Biotechnology Research Center) ;
  • Saberi, Samaneh (HPGC Group, Medical Biotechnology Department, Biotechnology Research Center) ;
  • Esmaeili, Maryam (HPGC Group, Medical Biotechnology Department, Biotechnology Research Center) ;
  • Oghalaie, Akbar (HPGC Group, Medical Biotechnology Department, Biotechnology Research Center) ;
  • Abdirad, Afshin (Cancer Institute, Amiralam Hospital) ;
  • Mostafavi, Ehsan (Epidemiology Department, Pasteur Institute of Iran) ;
  • Hosseini, Mahmoud Eshagh (Gastroenterology Department, Amiralam Hospital) ;
  • Mohagheghi, Mohammad Ali (Cancer Research Center, Tehran University of Medical Sciences) ;
  • Mohammadi, Marjan (HPGC Group, Medical Biotechnology Department, Biotechnology Research Center)
  • Published : 2013.03.30


Background: Multiple etiologic factors are suspected to cause gastric cancer, the most important of which is infection with virulent types of Helicobacter pylori. Materials and Methods: We have compared 102 gastric cancer patients with 122 non-ulcer, non-cancer dyspeptic patients. Gastric specimens were evaluated for H. pylori infection by tissue-based detection methods. Patient sera underwent antigen-specific ELISA and western blotting using a Helicoblot 2.1 kit and antibody responses to various H. pylori antigens were assessed. Results: The absolute majority (97-100%) of both groups were H. pylori seropositive. Multivariate regression analysis demonstrated serum antibodies to the low molecular weight 35kDa protein to be protective and reduce the risk of gastric cancer by 60% (OR:0.4; 95%CI:0.1-0.9). Conversely, seroreactivity to the 89kDa (VacA) protein was significantly higher in gastric cancer patients (OR:2.7; 95%CI:1.0-7.1). There was a highly significant association (p<0.001) between seroreactivity to the 116kDa (CagA) and 89kDa (VacA) proteins, and double positive subjects were found at nearly five fold (OR:4.9; 95%CI:1.0-24.4) enhanced risk of gastric cancer as compared to double negative subjects. Conclusions: Seroreactivity to H. pylori low (35kDa) and high (116kDa/89kDa) molecular weight antigens were respectively revealed as protective and risk indicators for gastric cancer.


  1. Baiocchi G, Vettoretto N, Colombrita D, et al (2002). Is there an association between Helicobacter pylori cytotoxin Cag A seropositivity and risk for gastric cancer? Annali Italiani Di Chirurgia, 73, 571-761.
  2. Chomvarin C, Ottiwet O, Hahnvajanawong, C, et al (2009). Seroreactivity to specific antigens of Helicobacter pylori infection is associated with an increased risk of the dyspeptic gastrointestinal diseases. Int J Infectious Diseases, 13, 647-55.
  3. Epplein M, Signorello LB, Zheng W, et al (2011). Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomarkers and Prev, 20, 826-34.
  4. Figueroa G, Troncoso M, Toledo M, et al (2002). Prevalence of serum antibodies to Helicobacter pylori VacA and CagA and gastric diseases in Chile. J Med Microbiology, 51, 300-4.
  5. Fox JG, Wang TC (2007). Inflammation, atrophy, and gastric cancer. J Clinical Investigation, 117, 60-68.
  6. Garza-Gonzalez E, Bosques-Padilla FJ, Perez-Perez GI, et al (2004). Association of gastric cancer, HLA-DQA1, and infection with Helicobacter pylori CagA+ and VacA+ in a Mexican population. J Gastroenterology, 39, 1138-42.
  7. Herbrink P, Van Doorn L (2000). Serological methods for diagnosis of Helicobacter pylori infection and monitoring of eradication therapy. Eur J Clinical Microbiol and Infectious Diseases, 19, 164-73.
  8. Hoang T, Rehnberg AS, Wheeldon TU, et al (2006). Comparison of the performance of serological kits for Helicobacter pylori infection with European and Asian study populations. Clin Microbiology and Infection, 12, 1112-17.
  9. Jaber SM (2005). The pattern of CagA and VacA proteins in Helicobacter pylori seropositive asymptomatic children in western Saudi Arabia. Saudi medical j, 26, 1372-80.
  10. Janulaityte Günther D, Kupcinskas L, Pavilonis A, et al (2007). Combined serum IgG response to Helicobacter pylori VacA and CagA predicts gastric cancer. FEMS Immunol and Med Microbiol, 50, 220-25.
  11. Michel A, Waterboer T, Kist M, et al (2009). Helicobacter pylori multiplex serology. Helicobacter, 14, 525-35.
  12. Mitchell H, English D, Elliott F, et al (2008). Immunoblotting using multiple antigens is essential to demonstrate the true risk of Helicobacter pylori infection for gastric cancer. Alimentary Pharmacology and Therapeutics, 28, 903-10.
  13. Mohammadi M, Kashani SS, Garoosi YT, et al (2012). In Vivo Measurement of Helicobacter pylori Infection. Methods in Molecular Biology (Clifton, NJ), 921, 239-56.
  14. Mohammadi M, Talebkhan, Y, Khalili G, et al (2008). Advantage of using a home-made elisa kit for detection of Helicobacter pylori infection over commercially imported kits. Indian J Medical Microbiology, 26, 127-34.
  15. Nagini S (2012). Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointestinal Oncol, 4, 156-61.
  16. Ogunc D, Artan R, Ongut G, et al (2003). Evaluation of a Western blot technique (Helicoblot 2.1) for the diagnosis of Helicobacter pylori infection in children. Pathology J RCPA, 35, 157-60.
  17. Rocha, A, Rocha GA, Leite JL , et al (2004). Immunoblotting for the serodiagnosis of Helicobacter pylori infection in Brazilian patients with and without gastric carcinoma. Memorias do Instituto Oswaldo Cruz, 99, 189-93.
  18. Sachs G, Scott D R (2012). Helicobacter pylori: eradication or preservation. F1000 Medicine Reports, 4, 27-34.
  19. Sezikli M, Guliter S, Apan T, et al (2006). Frequencies of serum antibodies to Helicobacter pylori CagA and VacA in a Turkish population with various gastroduodenal diseases. Int J Clinical Practice, 60, 1239-43.
  20. Siman JH, Engstrand L, Berglund G, et al (2005). Evaluation of western blot CagA seropositivity in Helicobacter pylori-seropositive and-seronegative subjects. Clinical and Diagnostic Laboratory Immunology, 12, 304-9.
  21. Siman JH, Engstrand L, Berglund G, et al (2007). Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma. Scandinavian J Gastroenterology, 42, 933-40.
  22. Suriani R, Colozza, M, Cardesi E, et al (2008). CagA and VacA Helicobacter pylori antibodies in gastric cancer. Canadian J Gastroenterology, 22, 255-565.
  23. Talebkhan Y, Mohammadi M, Mohagheghi MA, et al (2008). cagA gene and protein status among Iranian Helicobacter pylori strains. Digestive Disease Sci, 53, 925-32.
  24. Treepongkaruna S, Nopchinda S, Taweewongsounton A, et al (2006). A rapid serologic test and immunoblotting for the detection of Helicobacter pylori infection in children. J Tropical Pediatrics, 52, 267-71.
  25. Veijola L, Oksanen A, Sipponen P, et al (2008). Evaluation of a commercial immunoblot, Helicoblot 2.1, for diagnosis of Helicobacter pylori infection. Clin and Vaccine Immunol, 15, 1705-10.
  26. Vilaichone RK, Mahachai V, Kositchaiwat C, et al (2003). Relation between seroreactivity to low-molecularweight Helicobacter pylori-specific antigens and disease presentation. Clin and Diagnostic Lab Immunol, 10, 1025-8.
  27. Yamaoka Y, Kodama T, Graham DY,et al (1998). Search for putative virulence factors of Helicobacter pylori (The lowmolecular-weight (33-35 K) antigen). Digestive Diseases and Sciences, 43, 1482-7.
  28. Yang KC, Chu A, Liao CS, et al (2006). Evaluation of the role of H pylori infection in pathogenesis of gastric cancer by immunoblot assay. World J Gastroenterology, 12, 7029-36.
  29. Ye W, Held M, Enroth H, et al (2005). Histology and culture results among subjects with antibodies to CagA but no evidence of Helicobacter pylori infection with IgG ELISA. Scandinavian J Gastroenterology, 40, 312-8.

Cited by

  1. Prevalence and Risk Factors of H. pylori from Dyspeptic Patients in Northwest Ethiopia: A Hospital Based Cross-sectional Study vol.15, pp.11, 2014,
  2. Lack of any Prognostic Relationship between Adiponectin Receptor (Adipo R1/R2) Expression for Early/Advanced Stage Gastric Cancer vol.15, pp.11, 2014,
  3. Virulence Genes of Helicobacter pylori in Gastritis, Peptic Ulcer and Gastric Cancer in Laos vol.15, pp.20, 2014,
  4. Infection vol.19, pp.10834389, 2014,
  5. Helicobacter pylori Infection Impacts on Functional Dyspepsia in Thailand vol.15, pp.24, 2015,
  6. Risk Factors and Epidemiology of Gastric Cancer in Pakistan vol.16, pp.12, 2015,
  7. Promyelocytic Leukemia (PML) Gene Mutations may not Contribute to Gastric Adenocarcinoma Development vol.16, pp.8, 2015,
  8. Diagnosis of Helicobacter pylori Infection vol.17, pp.4, 2016,
  9. in middle-aged Caucasian general population sample vol.53, pp.7, 2018,